The Curbsiders Internal Medicine Podcast
#204 NephMadness 2020: SGLT2 Inhibitors
Apr 6, 2020
Explore the exciting world of SGLT2 inhibitors with Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf. They discuss the mechanisms and benefits of these inhibitors for glucose control, cardiovascular health, and chronic kidney disease. The speakers delve into the hemodynamics and regulation of glomerular filtration and explore the various mechanisms of action of SGLT2 inhibitors, emphasizing their impact on inflammation, fibrosis, insulin sensitivity, and more. They also discuss the cancellation of Neffmatin and make predictions for the winners in the NephMadness 2020 SGLT2i region.
50:21
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease by reducing glucose reabsorption and sodium levels, leading to improved kidney function.
- SGLT2 inhibitors have potential benefits in non-diabetic kidney disease, with studies suggesting improved kidney function and preservation of nephrons.
Deep dives
Summary of the podcast: SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease. They work by reducing glucose reabsorption and sodium levels, leading to reduced intraglomerular pressure and improvement in kidney function. The drugs have also been found to have anti-inflammatory and fibrosis effects. While they can cause some side effects like mycotic infections and euglycemic decay, overall they have a good safety profile. Further studies are needed to explore their use in non-diabetic kidney disease and in kidney transplant patients.
SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease. They work by reducing glucose reabsorption and sodium levels, leading to reduced intraglomerular pressure and improvement in kidney function. The drugs have also been found to have anti-inflammatory and fibrosis effects. Studies are ongoing to explore their use in non-diabetic kidney disease and in kidney transplant patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
